Trials / Completed
CompletedNCT03681483
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
A Phase 1 Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO5126766 | RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal. |
Timeline
- Start date
- 2018-10-31
- Primary completion
- 2024-07-08
- Completion
- 2024-07-08
- First posted
- 2018-09-24
- Last updated
- 2024-07-10
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03681483. Inclusion in this directory is not an endorsement.